* Puma Biotechnology Inc PBYI.OQ reported a quarterly
adjusted
loss of 9 cents per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of 5 cents. The mean expectation of three analysts for the
quarter was for a loss of 13 cents per share. Wall Street
expected results to range from -19 cents to -8 cents per share.
* Revenue fell 13.7% to $47.10 million from a year ago;
analysts
expected $44.70 million.
* Puma Biotechnology Inc's reported EPS for the quarter was
a loss
of 9 cents.
* The company reported a quarterly loss of $4.5 million.
* Puma Biotechnology Inc shares had risen by 10.0% this
quarter and lost 17.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 30.3%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Puma
Biotechnology Inc is $4.00
This summary was machine generated from LSEG data August 2 at
02:06 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.13 -0.09 Beat
Mar. 31 2024 -0.22 -0.10 Beat
Dec. 31 2023 0.30 0.26 Missed
Sep. 30 2023 0.08 0.12 Beat